Aardvark Therapeutics appoints Abivax Chief Strategy Officer David Zhang to board
Bitget2026/10/08 12:01Aardvark Therapeutics appointed David Zhang to its board as an independent director, effective Oct. 7, 2026. Zhang is chief strategy officer at Abivax, overseeing biometrics, regulatory affairs, quality assurance, HEOR. He previously led biometrics and data management at Alumis, served as interim CIO, supported the company through its IPO. Earlier roles include biometrics leadership at MyoKardia on CAMZYOS clinical strategy and NDA work, roles at Genentech/Roche. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aardvark Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610080800PRIMZONEFULLFEED9841760) on October 08, 2026, and is solely responsible for the information contained therein.
- Aardvark Therapeutics appointed David Zhang to its board as an independent director, effective Oct. 7, 2026.
- Zhang is chief strategy officer at Abivax, overseeing biometrics, regulatory affairs, quality assurance, HEOR.
- He previously led biometrics and data management at Alumis, served as interim CIO, supported the company through its IPO.
- Earlier roles include biometrics leadership at MyoKardia on CAMZYOS clinical strategy and NDA work, roles at Genentech/Roche.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Canaccord Genuity: Lowers Oklo's target price to $66
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss
Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.
Crypto prices
More
